There were no significant differences between IL-17 inhibitors and the placebo with regard to death (0.17%, 2/1153 vs. 0.17%, 1/578) (RR = 0.70, 95% CI 0.14 to 3.52, p = 0.86) (Fig. 3b), discontinuation due to adverse event (2.5%, 29/1153 vs. 2.1%, 12/578) (RR = 1.18, 95% CI 0.62 to 2.26, p = 0.62) (Fig. 3c), or serious adverse events (including reactivation tuberculosis, bacterial sepsis, or invasive fungal infections) (2.3%, 27/1153 vs. 3.1%, 18/578) (RR = 0.74, 95% CI 0.42 to 1.33, p = 0.32) (Fig. 3e). Here, IL17A is linked to bacterial infectious disease with sepsis.